Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation

Authors

  • Phunchai Charatcharoenwitthaya,

    1. Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Sylvania Pimentel,

    1. William J. Von Liebig Liver Transplantation Center, Mayo Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Jayant A. Talwalkar,

    Corresponding author
    1. Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic and Foundation, Rochester, MN
    2. William J. Von Liebig Liver Transplantation Center, Mayo Clinic and Foundation, Rochester, MN
    • Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street. SW Rochester, Minnesota, USA, 55905
    Search for more papers by this author
    • Telephone: (507) 284-4823; FAX: (507) 284-0538

  • Felicity T. Enders,

    1. Division of Biostatistics, Mayo Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Keith D. Lindor,

    1. Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Ruud A.F. Krom,

    1. William J. Von Liebig Liver Transplantation Center, Mayo Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Russell H. Wiesner

    1. Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic and Foundation, Rochester, MN
    2. William J. Von Liebig Liver Transplantation Center, Mayo Clinic and Foundation, Rochester, MN
    Search for more papers by this author

  • See Editorial on Page 1214

Abstract

The recurrence of primary biliary cirrhosis (PBC) in the hepatic allograft may impact patient and graft survival with long-term follow-up. The efficacy of ursodeoxycholic acid (UDCA) for treatment of recurrent PBC after liver transplantation (LT) remains less well known. The aims of this study were as follows: 1) to determine the significance of recurrent PBC on overall survival among PBC patients who underwent LT, and 2) to determine the efficacy of UDCA treatment after LT in patients with recurrent PBC. A retrospective cohort study was conducted of 154 PBC patients who underwent LT with at least 1 yr of follow-up after transplantation from 1985 through 2005. A total of 52 patients with recurrent PBC were identified. After adjusting for age and gender, recurrent PBC was not associated with death or liver retransplantation (hazard ratio, 0.97, 95% confidence interval, 0.41–2.31; P = 0.9). A total of 38 patients with recurrent PBC received UDCA at an average dose of 12 mg/kg/day for a mean duration of 55 months. Over a 36-month period, an estimated 52% of UDCA-treated patients experienced normalization of serum alkaline phosphatase and alanine aminotransferase compared to 22% of untreated patients. There was no significant difference in the rate of histological progression between subgroups. UDCA did not influence patient and graft survival. In conclusion, the development of recurrent PBC has little impact on long-term survival or need for retransplantation. While UDCA therapy is associated with biochemical improvement, its role in delaying histologic progression remains unknown. In this short period of treatment, UDCA was not associated with improved patient and graft survival compared to untreated patients. Liver Transpl 13:1236–1245, 2007. © 2007 AASLD.

Ancillary